Elías Eyþórsson Aaron Goodman - “Papa Heme” iStopMM I’ve added a link to your calculator to our myelomarisk.com website.

Aaron Goodman - “Papa Heme” Vincent Rajkumar Maybe the @istopMM ≥10% bone marrow plasma cell risk calculator (istopmm.com/riskmodel/ ) could be of use as well? As detailed in our recent publication acpjournals.org/doi/10.7326/M2…

One of the most practice changing studies in the field of plasma cell dyscrasias is now published as a manuscript.

Great work iStopMM

acpjournals.org/doi/10.7326/M2…

This model predicts likelihood of finding more than 10% plasma cells, and prevents many from getting a bone marrow!

New serum FLC reference ranges for adults (including older adults) with normal renal function, courtesy of iStopMM. Hopefully these will reduce unnecessary MGUS workup and patient anxiety. #ASH23 #mmsm #nephpearls #gerionc

Today’s presentation from the iStopMM team! A poster on what happens to the M-protein after a Covid infection.

👇Great collaboration between iStopMM and Orfao Lab published in @BloodCancerJnL suggesting a role for the study of circulating tumor plasma cells and B cells during the diagnostic workup of MGUS #mmsm

Very timely given all that we are seeing at #ASH23

nature.com/articles/s4140…

And guess what!? They all got an abstract achievement award! #ASH2023 If you zoom in you might see how happy they are!

Sæmundur Rögnvaldsson, MD, PhD Jón Þórir Óskarsson Sigrun Thorsteinsdottir Þórir Long iStopMM

Very important work by University of Iceland Sigurdur Kristinsson! We need to redefine LC-MGUS. Our clinic is flooded with ?kappa-MGUS? #ASH23 #mmsm

New sFLC based on iStopMM. Using current reference ranges there was a high rate (as high as ~40% for KLC), and there was a significant reduction in the number of patients diagnosed with LC-MGUS (~80%), with no lymphoproliferative dx on f/u (although 3.5yr only)
#ASH23 #mmsm

Everyone is talking about MRD at #ASH23
You need to make sure your sample is not hemodiluted

We now have a way of measuring hemodilution using flow cytometry, publication from iStopMM here: nature.com/articles/s4140…

Calculator: istopmm.com/bmqi/

Jón Þórir Óskarsson Blood Cancer Journal

Today’s presentations from the iStopMM team! 2 orals and a poster!
Þórir Long proposes new FLC reference intervals and new definition of light-chain MGUS Jón Þórir Óskarsson uses NGF to further increase our understanding of LC-MGUS. Sigrun Thorsteinsdottir presents risk factors for SMM

Today’s oral presentations from the iStopMM team! Sæmundur Rögnvaldsson, MD, PhD will present the current results from the trial. Also the thrombotic risk is covered. Don’t miss it!

At #ASH23 , we have 6 abstracts from the iStopMM study, 4 oral presentations and 2 posters!

All presentations are done by PhD students and postdocs: Sæmundur Rögnvaldsson, MD, PhD Þórir Long Jón Þórir Óskarsson Sigrun Thorsteinsdottir Robert Palmason International Myeloma Foundation

Lets start!

1. The definitions of normal versus abnormal light chain levels have changed, and many patients who would previously be called as light chain MGUS now have light chains within normal limits.

Excellent practice changing iStopMM study

ash.confex.com/ash/2023/webpr…

1⭐️If you are seeing a patient with MGUS, and are wondering what is the likelihood that a bone marrow biopsy will change their diagnosis (i.e find more than 10% plasma cells and change to SMM or MM), here is the perfect calculator from iStopMM:

istopmm.com/riskmodel/

Manni Mohyuddin iStopMM Basically ignore every other study with associations. This is wonderful work from @istopmm

Great work- iStopMM

Patients diagnosed with MGUS clinically have more comorbidities vs MGUS diagnosed through screening

Previous associations of some diseases with MGUS (eg osteoporosis) were selection bias rather than biological association!

pubmed.ncbi.nlm.nih.gov/37439374/

#mmsm

#EMN2023 To screen or not to screen for myeloma👉🏻iStopMM screened the Icelandic population over 40👉🏻0.5% had SMM but screening for MM is currently not recommended based the data Sigrun Thorsteinsdottir giving an excellent presentation

The first study on the prevalence of smoldering myeloma just published in Nature Medicine !

Full link: rdcu.be/c4026

We found the prevalence of SMM to be 0.5% in people >40 years

Based on nationwide screening in Iceland, the prevalence of smoldering multiple myeloma (precursor to MM, no symptoms) is higher than expected and has implications for early treatment
nature.com/articles/s4159… Nature Medicine